|Price and Volume|
|52 Week High||2.53|
|52 Week Low||1.27|
|Avg. Daily Vol. (Mil)||0.40|
|Beta (3 year)||0.93|
|Share Related Items|
|Mkt Cap (Mil)||36.37|
|Shares Out (Mil)||26.54|
|LT Debt/ Equity||0.00|
|Total Debt / Equity||0.00|
|Per Share Data|
|OxiGene Inc is a biopharmaceutical company. The Company is engaged in development of vascular disrupting agents (VDAs) for the treatment of cancer. Ithas two clinical stage product candidates that are developed in three potential oncology indications.|
|701 Gateway Boulevard
South San Francisc, CA 94080
|Industry : Drugs|
|Sector: Health Care|
|CEO: Dr. William D. Schwieter|
|Current Month (Mil)||1.09|
|Previous Month (Mil)||1.06|
|Short Interest Ratio (Days)||5.20|
|Return on Equity||n.a.|
|Return on Assets||-35.00|
|Return on Investments||-36.00|
|Rating||Current||1-Mo Ago||2-Mo Ago||3-Mo Ago|
|GET OXGN ANALYST REPORT|
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.